Annual Report 2023

• The United Laboratories (3933.HK ) was included in the Hang Seng Hong Kong Listed Biotechnology Index. • The United Laboratories received the "Best ESG Company Award" from Zhitongcaijing. • The oral solution production line of The United Animal Healthcare (Inner Mongolia) passed GMP certification. DECEMBER • The United Laboratories’ Amoxicillin was ranked among the “Health Industry Brand List for 2023” and was honored with the “Antibiotic Brand Gold Award”. • The application for product launching of The United Laboratories’ Liraglutide Injection was accepted. AUGUST • UBT251 Injection, a class I innovative drug for the treatment of adult type 2 diabetes, overweight or obesity, and non-alcoholic fatty liver disease, was approved for clinical trials in China. • Class I innovative drug UBT251 Injection for type 2 diabetes and overweight or obesity indications was approved by the US FDA for clinical trials. • TUL01101 tablets, a new class 1 drug for the treatment of moderate-to-severe atopic dermatitis, was approved for clinical trials. • The United Laboratories’ Ibuprofen Extended-release Capsule (specification: 0.3g) and Meropenem for Injection (specification: 0.25g, 0.5g) passed the quality and efficacy consistency evaluation of generic drugs. • The United Laboratories (Inner Mongolia) has reached a framework agreement with the Institute of Microbiology, Chinese Academy of Sciences on strategic cooperation in the field of synthetic biology. SEPTEMBER • The shareholders of The United Laboratories approved to adopt the 2023 Share Award Scheme. • The United Laboratories (Inner Mongolia) passed EU-GMP on-site inspection for Amoxicillin and Ampicillin. • The United Laboratories (Inner Mongolia) has been granted a license for the production of Tavamycin Tartrate veterinary drugs and passed the GMP inspection. OCTOBER • Zhuhai United Laboratories was ranked 27th in the “2022 Top 100 Pharmaceutical Enterprises in China”. • Zhuhai United Laboratories was ranked 69th in the “Top 500 Manufacturing Enterprises in Guangdong Province for 2023”. • The United Laboratories (Gaolan Port) project (production base for APIs and veterinary drugs) witnessed the laying of the foundation stone and the commencement of construction. NOVEMBER 3 The United Laboratories International Holdings Limited Annual Report 2023 CORPORATE CALENDAR OF 2023